# Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

> **NCT04151667** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 33 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab Injection
- **DRUG:** Dexamethasone Oral
- **DRUG:** Lenalidomide Pill
- **DRUG:** Bortezomib Injection

## Key facts

- **NCT ID:** NCT04151667
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-22
- **Primary completion:** 2023-11-08
- **Final completion:** 2026-05-07
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04151667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04151667, "Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04151667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*